Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial
Solidarity Finland Investigators; Nevalainen, Olli P.O.; Horstia, Saana; Laakkonen, Sanna; Rutanen, Jarno; Mustonen, Jussi M.J.; Kalliala, Ilkka E.J.; Ansakorpi, Hanna; Kreivi, Hanna Riikka; Kuutti, Pauliina; Paajanen, Juuso; Parkkila, Seppo; Paukkeri, Erja Leena; Perola, Markus; Pourjamal, Negar; Renner, Andreas; Rosberg, Tuomas; Rutanen, Taija; Savolainen, Joni; Haukka, Jari K.; Guyatt, Gordon H.; Tikkinen, Kari A.O. (2022-10)
Solidarity Finland Investigators
Nevalainen, Olli P.O.
Horstia, Saana
Laakkonen, Sanna
Rutanen, Jarno
Mustonen, Jussi M.J.
Kalliala, Ilkka E.J.
Ansakorpi, Hanna
Kreivi, Hanna Riikka
Kuutti, Pauliina
Paajanen, Juuso
Parkkila, Seppo
Paukkeri, Erja Leena
Perola, Markus
Pourjamal, Negar
Renner, Andreas
Rosberg, Tuomas
Rutanen, Taija
Savolainen, Joni
Haukka, Jari K.
Guyatt, Gordon H.
Tikkinen, Kari A.O.
10 / 2022
6152
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202211018042
https://urn.fi/URN:NBN:fi:tuni-202211018042
Kuvaus
Peer reviewed
Tiivistelmä
We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.
Kokoelmat
- TUNICRIS-julkaisut [18884]